Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on July 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Alison L. Hannah appointed Executive Vice President and Chief Medical Officer effective July 1, 2026.
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Alison L. Hannah appointed Executive Vice President and Chief Medical Officer effective July 1, 2026
- Hannah resigned from Rigel’s Board upon appointment, ending service that began in May 2021
- Lisa Rojkjaer ceased serving as Chief Medical Officer and separated from Rigel effective June 25, 2026
- Leadership transition places an experienced oncology-development executive in Rigel’s top medical role
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.